Prot #N6022-1CF1-04: A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study of N6022 to Evaluate Safety and Pharmacokinetics in Subjects with Cystic Fibrosis Homozygous for the F508del-CFTR Mutation

Project: Research project

Project Details

StatusFinished
Effective start/end date3/6/13 → 3/6/16

Funding

  • Nivalis Therapeutics, Inc. (Prot #N6022-1CF1-04)